secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001664710-24-000075
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025
--------------------------------------------------------------------------------

- Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.
- Company expects to complete enrollment by end of September 2024.
- Topline data now expected in Q2 2025, earlier than previously anticipated.
- CEO Jasbir Seehra cited strong demand and rapid enrollment as catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000075/0001664710-24-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000075/kros-20240903.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer